Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 10.25 NOK
Change Today +0.10 / 0.99%
Volume 1.7K
NATTO On Other Exchanges
As of 10:25 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

nattopharma asa (NATTO) Snapshot

10.90 NOK
Previous Close
10.15 NOK
Day High
10.90 NOK
Day Low
10.05 NOK
52 Week High
08/26/14 - 16.69 NOK
52 Week Low
10/13/14 - 9.33 NOK
Market Cap
Average Volume 10 Days
-1.54 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for NATTOPHARMA ASA (NATTO)

Related News

No related news articles were found.

nattopharma asa (NATTO) Related Businessweek News

No Related Businessweek News Found

nattopharma asa (NATTO) Details

NattoPharma ASA produces nutrition supplements. It offers MenaQ7 that provides natural vitamin K2 (Menaquinone-7) as a fermentation extract for use in dietary supplements, and functional and fortified foods. The company sells its products through retail pharmacies. NattoPharma ASA was founded in 2004 and is based in Høvik, Norway.

10 Employees
Last Reported Date: 05/6/15
Founded in 2004

nattopharma asa (NATTO) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 655.0K NOK
Chief Operating Officer
Total Annual Compensation: 515.0K NOK
Senior Vice President of Global Marketing
Total Annual Compensation: 1.8M NOK
Senior Vice President of Sales & Marketing - ...
Total Annual Compensation: 718.0K NOK
Senior Vice President of R&D and Regulatory A...
Total Annual Compensation: 500.0K NOK
Compensation as of Fiscal Year 2014.

nattopharma asa (NATTO) Key Developments

NattoPharma ASA Announces Board Appointments

Christopher von Schirach-Szmigiel was elected as member of the Board of Directors in NattoPharma ASA for a period of two years at the General Assembly 25th June 2015. Frode Marc Bohan remains Chairman of the Board as his position was not up for election. Katrazyna Maresz was elected as Board member for another two-year period. Christopher von Schirach-Szmigiel was Board Director in Uniliver Nordic, Stora Data, Ericsson Group, Audi-Volkswagen Scandinavia and Porsche. He has also served as Board dierector at Universities in Sweden, USA and Poland and has been expert and advisor for the Swedish government in shipping and shipbuilding.

NattoPharma ASA Approves Amendment to its Articles of Association

NattoPharma ASA announced that at the AGM to be held on June 25, 2015, the shareholders approved amendment of the Articles of Association.

NattoPharma ASA Proposes Amendment of the Articles of Association

NattoPharma ASA announced that at the AGM to be held on June 25, 2015, the shareholders will consider amendment of the Articles of Association.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NATTO:NO 10.25 NOK +0.10

NATTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NATTO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NATTO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATTOPHARMA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at